Recently, clinical experience with 177Lu- and 90Y-labeled pentixather for the CXCR4-targeted radionuclide therapy for advanced-stage DLBCL, MM, and AML, has been reported32,33. The gene discussed is CXCR4; the disease is acute myeloid leukemia.